1. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168(2):580-586.

2. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995-2000.

3. Burgio KL, Locher JL, Goode PS, et al. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000;48:370-374.

4. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmaco-dynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6(3):243-262.

5. Thuroff JW, Chartier-Kastler E, Corcus J, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 1998;(16 suppl 1):S48-S61.

6. Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. Journal of Urology 2002;168:1897-1913.

7. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161(6):1809-1812.

8. Larsson G, Hallen B, Nilvebrant L, Tolterodine in the treatment of overactive bladder: an analysis of the pooled phase II efficacy and safety data. Urology 1999;53(5):990-998.

9. Van Kerrebroeck P, Amarenco G, Thuroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998;17(5):499-512.

10. Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol 1998;81(1):42-48.

11. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50(6A suppl):90-96; discussion 97-99.

12. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A, on behalf of the Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57(3):414-421.

13. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended release tolterodine or oxybutynin: the Antimus-

carinic Clinical Effectiveness Trial (ACET). Curr Hosp Res Opin 2002;18(4):177-184.

14. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-695.

15. Chancellor MB, de Groat WC. Intravesical capsaicin and resinifera-toxin therapy: spicing up the ways that we treat the overactive bladder. J Urol 1999;162:3.

16. Schurch B, Stöhrer M, Kramer G, et al. Botulinum: a toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692.

17. Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of Trospium chloride in patient with detrusor instabiligy: a placebo-controlled, randomized, bouble blind, multicentre clinical trial. BJU Int 2000;85:659-664.

18. Hofner K, Oelke M, Machtens S, Grunewald V. Trospium chloride: an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol 2001;19:336-343.

19. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and toltero-dine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76(4):358-363.

Biofeedback Mastery

Biofeedback Mastery

Have you ever wondered what Biofeedback is all about? Uncover these unique information on Biofeedback! Are you in constant pain? Do you wish you could ever just find some relief? If so, you are not alone. Relieving chronic pain can be difficult and frustrating.

Get My Free Ebook

Post a comment